Hancock Jaffe Laboratories (HJLI) Prices $5.1M Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Hancock Jaffe Laboratories, Inc. Announces Pricing of $5.1 Million Registered Direct Offering Priced at the Market
October 7, 2020 8:32 AM EDTIRVINE, CA / ACCESSWIRE / October 7, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a registered direct offering of $5.1 million of its common stock and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and one warrant to purchase one share of common stock will be $0.535 which is priced at-the-market under Nasdaq rules.
Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in... More



